Your browser is no longer supported. Please, upgrade your browser.
Settings
NNVC NanoViricides, Inc. daily Stock Chart
NNVC [NYSE]
NanoViricides, Inc.
Index- P/E- EPS (ttm)-0.15 Insider Own22.07% Shs Outstand77.65M Perf Week-10.51%
Market Cap27.10M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float53.76M Perf Month-13.83%
Income-9.50M PEG- EPS next Q- Inst Own4.70% Short Float0.37% Perf Quarter-36.66%
Sales- P/S- EPS this Y7.80% Inst Trans0.83% Short Ratio1.56 Perf Half Y-62.88%
Book/sh0.30 P/B1.16 EPS next Y- ROA-38.50% Target Price5.30 Perf Year-72.08%
Cash/sh0.14 P/C2.56 EPS next 5Y- ROE-51.30% 52W Range0.34 - 1.43 Perf YTD-60.35%
Dividend- P/FCF- EPS past 5Y-3.40% ROI- 52W High-75.59% Beta0.17
Dividend %- Quick Ratio3.40 Sales past 5Y- Gross Margin- 52W Low2.65% ATR0.04
Employees30 Current Ratio3.40 Sales Q/Q- Oper. Margin- RSI (14)39.53 Volatility8.98% 9.22%
OptionableYes Debt/Eq0.00 EPS Q/Q36.00% Profit Margin- Rel Volume0.71 Prev Close0.34
ShortableYes LT Debt/Eq0.00 EarningsAug 20 Payout- Avg Volume126.67K Price0.35
Recom- SMA20-11.67% SMA50-16.95% SMA200-54.63% Volume90,214 Change2.65%
Feb-11-15Initiated Midtown Partners Strong Buy $5.30
Aug-07-18 07:00AM  NanoViricides Reports Its Topical Dermal Shingles Candidates Effective in Reducing Pain in Animal Study PR Newswire
Jul-23-18 07:00AM  NanoViricides, Inc. Welcomes Dr. Irach Taraporewala as the New CEO PR Newswire
Jul-12-18 07:00AM  NanoViricides Provides Update on Recent Events PR Newswire
Jun-26-18 07:00AM  Progress of NanoViricides' Shingles Drug Program Presented at the 31st International Conference on Antiviral Research PR Newswire
Jun-19-18 07:20AM  Wired News AbbVie Presents New Undetectable Minimal Residual Disease Data from Phase-3 MURANO Trial of Venetoclax with Rituximab at 23rd European Hematology Association Annual Congress ACCESSWIRE
May-22-18 07:00AM  NanoViricides Files Quarterly Report for Period Ending March 31, 2018; Company Has Over A Year's Worth of Cash in Hand, and It Is Scaling Up Production of Certain Herpecide Program Drug Candidates PR Newswire
05:02AM  NanoViricides: Fiscal 3Q Earnings Snapshot Associated Press
Apr-09-18 07:00AM  NanoViricides Reports Good Safety Profile of Topical Dermal Drug Candidates; Dr. Diwan, President, Will Present at the MicroCap Conference in New York City Today PR Newswire
Mar-19-18 11:12AM  NanoViricides Drug Candidates to be Tested in Animal Models of Dermal, Ocular and Genital Herpes Virus Infection at the University of Wisconsin PR Newswire -5.43%
Mar-05-18 06:19PM  Is NanoViricides Incs (NYSEMKT:NNVC) CEO Paid Enough Relative To Peers? Simply Wall St.
Feb-26-18 07:40AM  Blog Exposure - Shire Gets BLA and Priority Review Status from FDA for Lanadelumab for the Prevention of HAE Attacks ACCESSWIRE
Feb-21-18 07:25AM  NanoViricides reports 2Q loss Associated Press
07:00AM  NanoViricides Files Quarterly Report for Period Ending December 31, 2017 PR Newswire
Feb-14-18 02:49PM  How Does NanoViricides Inc (NYSEMKT:NNVC) Affect Your Portfolio Returns? Simply Wall St.
Feb-12-18 08:56AM  Who Are The Largest Shareholders In NanoViricides Inc (NYSEMKT:NNVC)? Simply Wall St.
Dec-06-17 07:00AM  Nanoviricides Initiates a Safety/Toxicology Study of Its Leading Shingles Candidates PR Newswire
Nov-20-17 06:34PM  Is NanoViricides Inc (NNVC) A Financially Sound Company? Simply Wall St.
07:00AM  NanoViricides Files Quarterly Report for Period Ending September 30, 2017 PR Newswire
Nov-08-17 05:30PM  NanoViricides Signs Extension of Herpes Virus (HSV) Testing Agreement with University of Wisconsin ACCESSWIRE
Nov-06-17 07:00AM  NanoViricides Provides Further Details on Its Herpes-Induced Acute Retinal Necrosis Animal Study to be Presented On November 10th at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology PR Newswire
Oct-26-17 07:00AM  Excellent Results in Inhibiting Shingles Virus in Human Skin: NanoViricides Extends Agreement with SUNY Upstate Medical Center PR Newswire
Oct-17-17 07:00AM  NanoViricides to Present Results On Successful Treatment Of Herpes-Induced Acute Retinal Necrosis at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology PR Newswire
Sep-29-17 07:30AM  NanoViricides Has Filed Annual Report, Says Company Has Sufficient Cash To Advance Into Clinical Trials PR Newswire
Sep-11-17 09:04AM  NanoViricides, Inc. Announces its CEO Dr. Seymour to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City on September 12, 2017 PR Newswire
Jul-10-17 07:00AM  NanoViricides Reports Its Drug Candidates Significantly Reduced the Extent of Shingles Virus Infection of Human Skin PR Newswire
Jun-26-17 09:00AM  NanoViricides' Poster "Novel Nanoviricides® Highly Effective Against Varicella Zoster Virus in Cell Culture" to be Presented Today at the 2017 Annual Meeting of American Society of Virology PR Newswire
Jun-20-17 07:00AM  NanoViricides Abstract Accepted for Poster Presentation at the 2017 Annual Meeting of American Society of Virology PR Newswire
Jun-13-17 07:00AM  NanoViricides CEO to Present Information on Its Topical Shingles Treatment At the 2017 Marcum Investor Conference in New York City PR Newswire
Jun-06-17 05:30PM  NanoViricides Reports Excellent Inhibitory Effects of Its Topical Shingles Treatment Candidates Against VZV in Multiple Cell Culture Studies PR Newswire
May-16-17 07:58AM  NanoViricides reports 3Q loss Associated Press
07:50AM  NanoViricides Files Quarterly Report for Period Ending 2017-03-31 PR Newswire
Apr-26-17 05:00PM  NanoViricides CEO Dr. Seymour to Present an Update on the Company at The Planet Microcap Showcase - 2017 in Las Vegas; Company Says it is Close to Declaring a Clinical Candidate for the Treatment of Shingles PR Newswire
Feb-18-17 01:04PM  NANOVIRICIDES, INC. Financials
Feb-16-17 07:00AM  NanoViricides Files Quarterly Report for Period Ending 2016-12-31 PR Newswire
Feb-15-17 05:03AM  NanoViricides reports 2Q loss Associated Press
Feb-14-17 06:02PM  NANOVIRICIDES, INC. Files SEC form 10-Q, Quarterly Report
Feb-13-17 05:33PM  NANOVIRICIDES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Secur -6.25%
07:00AM  NanoViricides Reports the Company's Director Dr. Boniuk Converted Series B Debenture to Equity Effectively Raising $5M in New Equity for the Company PR Newswire
Dec-15-16 04:54PM  NANOVIRICIDES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders +12.62%
Dec-05-16 11:43AM  NanoViricides, Inc. :NNVC-US: Earnings Analysis: Q1, 2017 By the Numbers : December 5, 2016
Dec-01-16 07:00AM  NanoViricides Publishes a Letter from the CEO to Shareholders on its Website PR Newswire
Nov-15-16 07:00AM  NanoViricides Files Quarterly Report for Period Ending 2016-09-30 PR Newswire
Nov-14-16 05:04PM  NANOVIRICIDES, INC. Files SEC form 10-Q, Quarterly Report
Nov-07-16 07:00AM  NanoViricides President Dr. Diwan Gave Invited Talks on Regulatory Aspects of Nanomedicines PR Newswire
Oct-31-16 07:00AM  NanoViricides Signs Agreement with SUNY Upstate Medical Center for Testing of Its Drug Candidates for the Treatment of Shingles PR Newswire
Oct-11-16 07:00AM  NanoViricides Has Filed Annual Report, Says Company Has Sufficient Cash To Advance Into Clinical Trials PR Newswire
Sep-16-16 04:53PM  NANOVIRICIDES, INC. Files SEC form 10-K, Annual Report -6.02%
Sep-13-16 12:01AM  NanoViricides to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City Today PR Newswire
Aug-25-16 07:00AM  NanoViricides Reports on Senator Murphy's Visit to the Company's Shelton Campus PR Newswire
Jun-20-16 07:00AM  NanoViricides Reports On Progress of Its Drug Candidates against Herpesviruses PR Newswire
Jun-09-16 07:00AM  NanoViricides to Present at the LDMicro Invitational Conference PR Newswire
Jun-08-16 06:04PM  NanoViricides, Inc. :NNVC-US: Earnings Analysis: Q3, 2016 By the Numbers : June 8, 2016
Jun-07-16 07:00AM  NanoViricides to Present at the BIO2016 International Convention - on June 8, 2016, at 11a.m. Pacific Time PR Newswire
May-31-16 07:00AM  NanoViricides Signs Agreement with St. Jude Children's Research Hospital for further Influenza Drug Development PR Newswire
May-26-16 04:05PM  NanoViricides, Inc. To Present at the 5th Annual SeeThruEquity Microcap Investor Conference in New York City on May 31, 2016 Accesswire
May-11-16 07:00AM  NanoViricides Files Quarterly Report for Period Ending 2016-03-31 PR Newswire
May-10-16 04:36PM  NANOVIRICIDES, INC. Files SEC form 10-Q, Quarterly Report
Apr-18-16 07:00AM  NanoViricides, Inc. Recognized as one of the Most Innovative Businesses-2016 by AI Global Media - Acquisitions International PR Newswire
Mar-21-16 07:00AM  NanoViricides, Inc. CEO Dr. Seymour Interview by Small Cap Nation is on YouTube PR Newswire
Feb-22-16 07:00AM  NanoViricides' Anti-Virus Technology Published in Handbook of Clinical Nanomedicine PR Newswire
Feb-16-16 07:00AM  NanoViricides Signs Agreement for Ocular Testing of Its Drug Candidates for the Treatment of Herpes Keratitis with the Baylor College of Medicine PR Newswire
Feb-11-16 07:00AM  NanoViricides Signs Agreement for Ocular Testing of Its Drug Candidates for the Treatment of Herpes Keratitis with the University of Pittsburgh PR Newswire
Feb-10-16 07:00AM  NanoViricides Files Quarterly Report for Period Ending 2015-12-31 PR Newswire
Feb-09-16 04:09PM  NANOVIRICIDES, INC. Files SEC form 10-Q, Quarterly Report
Feb-08-16 07:00AM  NanoViricides CEO to Present at the 18th Annual BIOCEO & Investor Conference on February 8, 2016 and at the Disruptive Growth and Healthcare Conference on February 11, 2016, both in New York City PR Newswire
Feb-01-16 07:00AM  NanoViricides Signs Agreement with the University of Wisconsin for Testing of Anti-Viral Candidates PR Newswire
Jan-29-16 05:01PM  NANOVIRICIDES, INC. Files SEC form 8-K, Material Modification to Rights of Security Holders, Amendments to Articles o
Jan-25-16 07:00AM  NanoViricides 2015 Annual Shareholders Meeting Was Held on January 23, 2016 - Company Discussed Accomplishments and Future Strategy PR Newswire
Jan-12-16 07:00AM  NanoViricides CEO Dr. Eugene Seymour to Present at the Biotech Showcase in San Francisco on Wednesday PR Newswire
Nov-27-15 10:10AM  Here is What Hedge Funds Think About NanoViricides Inc (NNVC) at Insider Monkey
Nov-10-15 07:00AM  NanoViricides Files Quarterly Report for Period Ending 2015-09-30 PR Newswire
Nov-09-15 03:10PM  NANOVIRICIDES, INC. Files SEC form 10-Q, Quarterly Report
Sep-16-15 07:00AM  NanoViricides Files Annual Report PR Newswire
Sep-14-15 05:21PM  NANOVIRICIDES, INC. Files SEC form 10-K, Annual Report
Aug-17-15 07:00AM  NanoViricides Accelerates its Herpes Drug Development Program PR Newswire
Aug-10-15 07:00AM  NanoViricides Reports that the Dramatic Effects of Its Topical Anti-Herpes Treatment were Reproduced Once Again in an Animal Model in a Different Laboratory PR Newswire
Jul-24-15 05:30PM  NANOVIRICIDES, INC. Files SEC form 8-K, Change in Directors or Principal Officers
May-18-15 08:12PM  10-Q for NanoViricides, Inc. at Company Spotlight
07:00AM  NanoViricides Files Quarterly Report for Period Ending 2015-03-31 PR Newswire
May-15-15 02:26PM  NANOVIRICIDES, INC. Files SEC form 10-Q, Quarterly Report
Apr-27-15 07:00AM  NanoViricides Discusses the Strong Effectiveness of Its Anti-Herpes Drug Candidates in a Lethal Animal Model of Dermal Herpes Infection PR Newswire
Apr-20-15 07:00AM  NanoViricides Reports that Its Topical Anti-Herpes Treatment Dramatically Improves Clinical Symptoms in an Animal Model PR Newswire
Apr-06-15 07:00AM  NanoViricides Provides an Update on Its Progress over the Last Quarter PR Newswire
Mar-09-15 07:00AM  NanoViricides Issued Registered Shares as Interest to Certain Debenture Holders PR Newswire
Feb-27-15 07:08PM  10-Q/A for NanoViricides, Inc. at Company Spotlight
Feb-25-15 07:08PM  10-Q/A for NanoViricides, Inc. at Company Spotlight
09:33AM  NanoViricides reports 2Q loss
09:00AM  NanoViricides Files Quarterly Report for Period Ending 2014-12-31 PR Newswire
Feb-24-15 07:40AM  NANOVIRICIDES, INC. Files SEC form 10-Q, Quarterly Report
Feb-23-15 05:21PM  NANOVIRICIDES, INC. Files SEC form 10-Q/A, Quarterly Report
05:17PM  NANOVIRICIDES, INC. Files SEC form 10-K/A, Annual Report
Feb-18-15 05:19PM  NANOVIRICIDES, INC. Files SEC form 8-K, Non-Reliance on Previous Financials, Audits or Interim Review EDGAR Online
Feb-17-15 07:00AM  NanoViricides Announces that a Research Report on the Company has been Published By Midtown Partners, Inc., a New York Investment Bank PR Newswire
Feb-11-15 01:36PM  Coverage initiated on NanoViricides by Midtown Partners Briefing.com
Jan-26-15 02:34PM  NANOVIRICIDES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure EDGAR Online
Jan-23-15 07:00AM  NanoViricides Reports that the FluCide® Candidate was found to be Very Safe in cGLP-like Safety and Toxicology Study in Rats Performed by BASi PR Newswire
Jan-22-15 07:00AM  NanoViricides Reports That It Has Shipped anti-Ebola Drug Candidates For Testing to a BSL-4 Hi-Security Biocontainment Laboratory PR Newswire
Jan-21-15 07:00AM  NanoViricides, Inc.'s Executive Officers Report Insider Purchases of Common Stock PR Newswire
Jan-07-15 05:19PM  NANOVIRICIDES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or Disp EDGAR Online
07:30AM  NanoViricides, Inc. Completes Purchase of cGMP-compliant Pilot Production Facility PR Newswire
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.